Point in time view as at 06/11/2023.
The Medicines for Human Use (Clinical Trials) Regulations 2004, Paragraph 5 is up to date with all changes known to be in force on or before 04 March 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
5.—(1) Section 23 of the Act (special provisions as to the effect of manufacturer’s licence) F1 shall be amended as follows.U.K.
(2) In subsection (1)—
(a)omit “clinical trials and”;
(b)for paragraph (b), substitute the following paragraph—
“(b)the products are manufactured or assembled to the order of—
(i)a person who is the holder of such a product licence, or
(ii)if the products are to be used for the purposes of a clinical trial, the sponsor of that trial,”.
(3) After subsection (5), insert the following subsection—
“(6) In this section, “clinical trial” and “sponsor”, in relation to a clinical trial, have the meaning given by Clinical Trials Regulations.”.
Textual Amendments
F1Section 23 of the Act has effect as if any reference in subsection (1) to a product licence included a reference to a marketing authorization; see regulation 9(1) of the 1994 Regulations.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
